LSL Pharma【LSL】銘柄情報

LSL Pharma Group Inc (LSL) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.30

( -1.64% )

買値

0.30

売値

0.32

出来高

320,000

0.30 日の範囲 0.31

0.30 52 週間の範囲 0.56

時価総額

36.366M

前日終値

0.305

始値

0.31

時刻

5000

0.3

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

$ 93,389

発行済株式数

121,220,176

配当利回り

PER

13.88

1 株当たり利益 (EPS)

歳入

26.8M

純利益

2.78M

LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products in Canada, the United States, and internationally. The company offers dietary supplements and vitamins in the tablet and capsule form; niche sterile ophtha... LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products in Canada, the United States, and internationally. The company offers dietary supplements and vitamins in the tablet and capsule form; niche sterile ophthalmic products in the form of ointments and drops; and cosmetic, pharmaceutical, and natural health products in liquid and semi-solid form for pharmacy banners and hospitals. The company is headquartered in Boucherville, Canada. 詳細を表示

セクター

Healthcare

業界

Pharmaceuticals

ウェブサイト

www.groupelslpharma.com

本社

Boucherville, Canada

設立

LSL Pharma Group Inc is listed in the Healthcare sector of the トロントベンチャー取引所 with ticker LSL. The last closing price for LSL Pharma was $0.31. Over the last year, LSL Pharma shares have traded in a share price range of $ 0.30 to $ 0.56.

LSL Pharma currently has 121,220,176 shares in issue. The market capitalisation of LSL Pharma is $36.37 million. LSL Pharma has a price to earnings ratio (PE ratio) of 13.88.

LSL PHARMA GROUP ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

LSL PHARMA GROUP ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS Canada...

LSL PHARMA GROUP SECURES NEW STERI-MED COMMERCIAL AGREEMENTS EXPECTED TO GENERATE OVER $4 MILLION IN RECURRING ANNUAL REVENUES AND APPOINTS ALAIN R. DUGAL AS NEW EVP & COO

LSL PHARMA GROUP SECURES NEW STERI-MED COMMERCIAL AGREEMENTS EXPECTED TO GENERATE OVER $4 MILLION IN...

LSL PHARMA GROUP REPORTS ITS FOURTH QUARTER AND YEAR-END 2025 RESULTS

LSL PHARMA GROUP REPORTS ITS FOURTH QUARTER AND YEAR-END 2025 RESULTS Canada NewsWire BOUCHERVILLE, QC...

JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE LIMITED TO SUPPLY PRIVATE LABEL LORATADINE 10 MG RDT IN CANADA

JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE...

LSL PHARMA GROUP GRANTS STOCK OPTIONS

LSL PHARMA GROUP GRANTS STOCK OPTIONS Canada NewsWire BOUCHERVILLE, QC, Feb. 3, 2026 BOUCHERVILLE, QC...

LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS FOR COMMERCIALIZATION IN THE UNITED STATES

LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS...

LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M OFFERING

LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M...

LSL PHARMA GROUP CLOSES $10M OF UPSIZED $12M BROKERED OFFERING AND ENTERS INTO DEFINITIVE AGREEMENT FOR THE ACQUISITION OF JUNO OTC

LSL PHARMA GROUP CLOSES $10M OF UPSIZED $12M BROKERED OFFERING AND ENTERS INTO DEFINITIVE AGREEMENT FOR THE...

LSL PHARMA GROUP ANNOUNCES ACQUISITION OF JUNO OTC INC. AND A BROKERED PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES OF $11M

LSL PHARMA GROUP ANNOUNCES ACQUISITION OF JUNO OTC INC. AND A BROKERED PRIVATE PLACEMENT OF CONVERTIBLE...

LSL PHARMA GROUP REPORTS FOURTH CONSECUTIVE RECORD QUARTERLY REVENUES AND Q3 2025 FINANCIAL RESULTS

LSL PHARMA GROUP REPORTS FOURTH CONSECUTIVE RECORD QUARTERLY REVENUES AND Q3 2025 FINANCIAL RESULTS Canada...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.0125	-4	0.3125	0.325	0.3	120427	0.31483755	CS
4	-0.05	-14.2857142857	0.35	0.35	0.3	118796	0.32687671	CS
12	-0.09	-23.0769230769	0.39	0.425	0.3	93068	0.36217108	CS
26	-0.055	-15.4929577465	0.355	0.56	0.3	85704	0.39560554	CS
52	-0.07	-18.9189189189	0.37	0.56	0.3	71886	0.38820629	CS
156	-0.15	-33.3333333333	0.45	0.56	0.29	45244	0.39864793	CS
260	-0.4	-57.1428571429	0.7	1	0.29	42922	0.40842298	CS

LSL - Frequently Asked Questions (FAQ)

What is the current LSL Pharma Group Inc share price?

The current share price of LSL Pharma Group Inc is $ 0.30

How many LSL Pharma Group Inc shares are in issue?

LSL Pharma Group Inc has 121,220,176 shares in issue

What is the market cap of LSL Pharma Group Inc?

The market capitalisation of LSL Pharma Group Inc is CAD 36.37M

What is the 1 year trading range for LSL Pharma Group Inc share price?

LSL Pharma Group Inc has traded in the range of $ 0.30 to $ 0.56 during the past year

What is the PE ratio of LSL Pharma Group Inc?

The price to earnings ratio of LSL Pharma Group Inc is 13.88

What is the cash to sales ratio of LSL Pharma Group Inc?

The cash to sales ratio of LSL Pharma Group Inc is 1.42

What is the registered address of LSL Pharma Group Inc?

The registered address for LSL Pharma Group Inc is 540, d’Avaugour Street, Boucherville, Quebec, J4B 0G6

What is the LSL Pharma Group Inc website address?

The website address for LSL Pharma Group Inc is www.groupelslpharma.com

Which industry sector does LSL Pharma Group Inc operate in?

LSL Pharma Group Inc operates in the Pharmaceuticals sector

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

LSL Pharma Group Inc (LSL)

LSL Pharma Group Inc (LSL) 銘柄情報

個人投資家向けのプロ仕様のツール。

主要統計と詳細

LSL Pharma Group Inc について

LSL 最新ニュース

LSL PHARMA GROUP ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

LSL PHARMA GROUP SECURES NEW STERI-MED COMMERCIAL AGREEMENTS EXPECTED TO GENERATE OVER $4 MILLION IN RECURRING ANNUAL REVENUES AND APPOINTS ALAIN R. DUGAL AS NEW EVP & COO

LSL PHARMA GROUP REPORTS ITS FOURTH QUARTER AND YEAR-END 2025 RESULTS

JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE LIMITED TO SUPPLY PRIVATE LABEL LORATADINE 10 MG RDT IN CANADA

LSL PHARMA GROUP GRANTS STOCK OPTIONS

LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS FOR COMMERCIALIZATION IN THE UNITED STATES

LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M OFFERING

LSL PHARMA GROUP CLOSES $10M OF UPSIZED $12M BROKERED OFFERING AND ENTERS INTO DEFINITIVE AGREEMENT FOR THE ACQUISITION OF JUNO OTC

LSL PHARMA GROUP ANNOUNCES ACQUISITION OF JUNO OTC INC. AND A BROKERED PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES OF $11M

LSL PHARMA GROUP REPORTS FOURTH CONSECUTIVE RECORD QUARTERLY REVENUES AND Q3 2025 FINANCIAL RESULTS

LSL - Frequently Asked Questions (FAQ)

LSL 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

LSL Pharma Group Inc (LSL)

LSL Pharma Group Inc (LSL) 銘柄情報

個人投資家向けのプロ仕様のツール。

主要統計と詳細

LSL Pharma Group Inc について

LSL 最新ニュース

LSL PHARMA GROUP ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

LSL PHARMA GROUP SECURES NEW STERI-MED COMMERCIAL AGREEMENTS EXPECTED TO GENERATE OVER $4 MILLION IN RECURRING ANNUAL REVENUES AND APPOINTS ALAIN R. DUGAL AS NEW EVP & COO

LSL PHARMA GROUP REPORTS ITS FOURTH QUARTER AND YEAR-END 2025 RESULTS

JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE LIMITED TO SUPPLY PRIVATE LABEL LORATADINE 10 MG RDT IN CANADA

LSL PHARMA GROUP GRANTS STOCK OPTIONS

LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS FOR COMMERCIALIZATION IN THE UNITED STATES

LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M OFFERING

LSL PHARMA GROUP CLOSES $10M OF UPSIZED $12M BROKERED OFFERING AND ENTERS INTO DEFINITIVE AGREEMENT FOR THE ACQUISITION OF JUNO OTC

LSL PHARMA GROUP ANNOUNCES ACQUISITION OF JUNO OTC INC. AND A BROKERED PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES OF $11M

LSL PHARMA GROUP REPORTS FOURTH CONSECUTIVE RECORD QUARTERLY REVENUES AND Q3 2025 FINANCIAL RESULTS

LSL - Frequently Asked Questions (FAQ)

LSL 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する